Iambic Therapeutics, Inc.

What the company does

Iambic Therapeutics is a technology and clinical-stage life sciences company applying what it calls a 'molecular superintelligence' platform—an integration of proprietary large-scale AI with automated chemistry and biology experimentation—to disrupt conventional drug discovery. Its wholly owned pipeline includes IAM1363, an oral, pan-mutant, brain-penetrant HER2 small-molecule inhibitor currently in a Phase 1/1b basket trial in HER2-altered solid tumors, with registrational trial initiation anticipated as early as 2027. Additional programs include IAM217, a brain-penetrant allosteric KIF18A inhibitor (IND submitted September 2026), and IAM-C1, a selective CDK2/4 dual inhibitor, with an IND planned for the fourth quarter of 2026. The company has also entered into discovery and development collaborations with partners including AbbVie, Takeda, Lundbeck, and Revolution Medicines.

Use of proceeds

Iambic estimates net proceeds of approximately $135.0 million (or $155.9 million if the over-allotment option is exercised in full) at the $16.00 per share IPO price, after underwriting discounts and commissions and estimated offering expenses. The company intends to use the net proceeds, together with existing cash, to advance clinical development of IAM1363 through completion of the ongoing Phase 1 trial, initiation of one or more Phase 2 trials intended to support potential applications for accelerated approval, and initiation of a Phase 3 trial intended to support a potential application for full approval; to advance IAM217 and IAM-C1 through the Phase 1 dose-escalation portions of their respective Phase 1/2 trials; to continue investment in the molecular superintelligence platform; and the remainder, if any, for working capital and general corporate purposes, with possible use for acquisitions or investments in businesses, products, services, or technologies.

Underwriters

Extracted from 424B4 0001193125-26-422865, filed Oct 15, 2026 and verified against that filing text.

Key risk factors

• History of losses and no profitability

  “We have a limited operating history and have incurred significant losses and negative cash flows, and we anticipate that we will continue to incur losses and may never achieve or maintain profitability.”

• Need for substantial additional capital

  “We will require substantial additional capital, which may not be available on acceptable terms, if at all.”

• Dependence on strategic partnerships

  “Our business depends on establishing and maintaining strategic partnerships, including with AbbVie, Takeda, Lundbeck, and a small number of partners have accounted for a substantial portion of our revenue.”

• Novel and unproven AI-driven drug discovery

  “Our approach to drug discovery, which integrates AI with automated experimentation, is novel and unproven and may not lead to successful, commercially viable drug products.”

• Early-stage pipeline and clinical development risk

  “Our most advanced program, IAM1363, is in an early-stage Phase 1/1b clinical trial, and our other programs, IAM217 and IAM-C1, are preclinical; drug development is lengthy, expensive, and uncertain, and most candidates never receive regulatory approval.”

• Heavy competition, including from well-resourced AI drug-discovery peers

  “We face significant competition from pharmaceutical and biotechnology companies and from other companies applying AI and machine learning to drug discovery, many of which have substantially greater resources than we do.”

• No prior FDA approvals and unpredictable regulatory process

  “The regulatory approval process is lengthy, time-consuming, and inherently unpredictable; we have never obtained approval for any drug candidate and, even if we do, would remain subject to extensive ongoing regulation.”

• Volatility, dilution, and substantial insider influence

  “There has been no public market for our common stock, its price may be volatile, you will experience immediate and substantial dilution, and our insiders continue to have substantial influence.”